This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Kymriah, First CAR-T Therapy Approved: 4 Pharma Stocks in Focus
by Zacks Equity Research
With the approval of Novartis AG' (NVS) Kymriah, investors have started to shift their focus on a number of companies which have been developing their pipeline candidates.
Pfizer's Acute Leukemia Drug Mylotarg Approved by the FDA
by Zacks Equity Research
Pfizer's (PFE) Mylotarg received FDA nod as a treatment for new or relapsed CD33-positive acute myeloid leukemia.
Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal
by Zacks Equity Research
Gilead's (GILD) $11.8 billion deal to buy Kite Pharma KITE) has made two other leading independent CAR-T developers, Juno and Bluebird Bio hot takeover targets.
Indecision Won't Kill You, But It Will Take Your Money
by Kevin Cook
The pitfalls and powers of decision-making for traders and investors could be a model for everyone else.
Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition
by Ryan McQueeney
Shares of Juno Therapeutics (JUNO) continued to soar on Tuesday. The stock has now gained nearly 40% since the announcement that fellow CAR-T cancer therapy designer Kite Pharma (KITE) is being acquired by biotech behemoth Gilead Sciences (GILD).
Biotech Stock Roundup: Regeneron Drops RSV Antibody, Gilead HIV Drug Gets Priority Review
by Arpita Dutt
This week, companies like Regeneron (REGN) and Ionis provided updates on their pipeline while Gilead announced priority review for its HIV drug.
Agios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y
by Zacks Equity Research
Agios (AGIO) reports wider-than-expected loss with revenues marginally lagging estimates. However, the top line improves year over year, thanks to reimbursement received from Celgene.
Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Corcept Therapeutics Incorporated's (CORT) top line was driven by the strong sales of its only market drug Korlym. Thus the company raised its 2017 revenue guidance.
The Zacks Analyst Blog Highlights: Bank of America, UnitedHealth, Intel, UPS and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bank of America, UnitedHealth, Intel, UPS and Celgene
Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View
by Zacks Equity Research
Celgene Corporation (CELG) beat earnings and revenue estimates in the second quarter and upped view.
Celgene (CELG) Beats on Q2 Earnings & Sales
by Ekta Bagri
Celgene beat on second-quarter 2017 earnings and sales.
What's in Store for Agios Pharma (AGIO) in Q2 Earnings?
by Zacks Equity Research
Encouraging performance of Agios' (AGIO) lead candidate Idhifa, which is under review in the U.S. for treatment of AML might drive the stock in Q2.
Is a Beat in the Cards for Pfizer (PFE) in Q2 Earnings?
by Zacks Equity Research
While Pfizer, Inc.'s (PFE) new drugs like Ibrance and acquisitions like Hospira are likely to drive sales in Q2, genericization of key drugs, pricing pressure and rising competition will hurt sales.
Amgen (AMGN) Stock Falls Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Amgen Inc. (AMGN) beat estimates on both earnings & sales in Q2. While Amgen slightly tightened the sales guidance, it raised the earnings outlook backed by its strong performance in the first half.
Is Celgene (CELG) Poised For a Beat This Earnings Season?
by Zacks Equity Research
Celgene Corporation (CELG) is likely to beat on earnings estimates when it reports results on July 27 on the back of growth in Revlimid driven by share gains in important markets.
Is a Beat in the Cards for Vertex (VRTX) in Q2 Earnings?
by Zacks Equity Research
Impressive performance of Vertex Pharmaceuticals' (VRTX) cystic fibrosis drugs Kalydeco and Orkambi may drive the stock to an earnings beat in Q2.
HCA Healthcare (HCA) Q2 Earnings: Will it Beat Estimates?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter earnings are likely to witness equivalent, admission growth and accretion from a number of acquisitions. Commercial business will likely be a dampener.
Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
While Amgen, Inc.'s (AMGN) growth drugs like Prolia & Xgeva might continue to do well. Biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
J&J (JNJ) Beats on Q2 Earnings, Lags Sales, Ups 2017 View
by Zacks Equity Research
Johnson & Johnson (JNJ) reported mixed second-quarter 2017 results. While earnings beat expectations, sales missed the same.
5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote
by Arpita Dutt
It's time to look at these 5 CAR-T stocks given the interest generated by a positive FDA advisory panel vote for Novartis' (NVS) experimental CAR-T treatment.
Top Stock Reports for Apple, JPMorgan & Celgene
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), JPMorgan (JPM) and Celgene (CELG).
Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA
by Zacks Equity Research
Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that the FDA has issued a complete response letter (CRL) for the biologics license application (BLA) for Evenity (romosozumab).
The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals
Corcept Therapeutics Focuses on Korlym's Label Expansion
by Zacks Equity Research
We issued an updated research report on Corcept Therapeutics Incorporated (CORT) on Jul 12.
Novartis CAR-T Therapy Drug Recommended by FDA Panel
by Zacks Equity Research
Novartis AG (NVS) announced that the FDA Oncologic Drugs Advisory Committee (ODAC) has unanimously (10-0) recommended the approval of immunocellular therapy candidate CTL019 (tisagenlecleucel).